Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Angiotensin I | 37 | 2020 | 240 | 4.450 |
Why?
|
Peptide Fragments | 38 | 2020 | 398 | 4.420 |
Why?
|
Peptidyl-Dipeptidase A | 22 | 2017 | 132 | 1.910 |
Why?
|
Angiotensin II | 29 | 2015 | 243 | 1.590 |
Why?
|
Antineoplastic Agents | 5 | 2020 | 607 | 1.320 |
Why?
|
Renin-Angiotensin System | 17 | 2012 | 178 | 1.290 |
Why?
|
Rats | 40 | 2020 | 1596 | 0.970 |
Why?
|
Animals | 54 | 2020 | 7466 | 0.900 |
Why?
|
Antihypertensive Agents | 6 | 2015 | 351 | 0.880 |
Why?
|
RNA, Messenger | 28 | 2015 | 508 | 0.870 |
Why?
|
Baroreflex | 8 | 2015 | 84 | 0.810 |
Why?
|
Renin | 14 | 2012 | 109 | 0.770 |
Why?
|
Solitary Nucleus | 7 | 2015 | 34 | 0.720 |
Why?
|
Libraries, Medical | 1 | 2020 | 1 | 0.710 |
Why?
|
Rats, Sprague-Dawley | 19 | 2020 | 745 | 0.700 |
Why?
|
Receptor, Angiotensin, Type 1 | 12 | 2013 | 65 | 0.700 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 5 | 2010 | 135 | 0.690 |
Why?
|
Heart Rate | 9 | 2020 | 334 | 0.680 |
Why?
|
Doxorubicin | 1 | 2020 | 82 | 0.680 |
Why?
|
Information Dissemination | 1 | 2020 | 52 | 0.680 |
Why?
|
Carboxypeptidases | 6 | 2005 | 21 | 0.670 |
Why?
|
Antioxidants | 1 | 2020 | 114 | 0.670 |
Why?
|
Heart Diseases | 2 | 2020 | 116 | 0.670 |
Why?
|
Hospitals | 1 | 2020 | 103 | 0.660 |
Why?
|
Adenocarcinoma | 3 | 2012 | 311 | 0.650 |
Why?
|
Oxidative Stress | 6 | 2012 | 231 | 0.650 |
Why?
|
Imidazoles | 9 | 2011 | 91 | 0.640 |
Why?
|
Lung Neoplasms | 4 | 2011 | 409 | 0.610 |
Why?
|
Myocytes, Cardiac | 2 | 2008 | 86 | 0.560 |
Why?
|
Hypertension | 11 | 2015 | 957 | 0.550 |
Why?
|
MAP Kinase Signaling System | 5 | 2015 | 61 | 0.540 |
Why?
|
Gene Expression Regulation | 9 | 2015 | 494 | 0.500 |
Why?
|
Receptor, Angiotensin, Type 2 | 6 | 2013 | 22 | 0.490 |
Why?
|
Blood Pressure | 19 | 2015 | 845 | 0.470 |
Why?
|
Peptide Hormones | 1 | 2014 | 11 | 0.470 |
Why?
|
Uterus | 6 | 2015 | 93 | 0.460 |
Why?
|
Proto-Oncogene Proteins | 6 | 2009 | 85 | 0.460 |
Why?
|
Receptors, G-Protein-Coupled | 8 | 2011 | 85 | 0.450 |
Why?
|
MEDLINE | 2 | 2002 | 3 | 0.420 |
Why?
|
Osteoclasts | 1 | 2012 | 22 | 0.410 |
Why?
|
Fibrosis | 8 | 2016 | 118 | 0.410 |
Why?
|
Cell Proliferation | 5 | 2014 | 599 | 0.410 |
Why?
|
Dual Specificity Phosphatase 1 | 7 | 2015 | 29 | 0.410 |
Why?
|
Fibroblasts | 2 | 2012 | 112 | 0.400 |
Why?
|
Leucine | 2 | 2010 | 20 | 0.400 |
Why?
|
Angiotensin II Type 1 Receptor Blockers | 11 | 2015 | 65 | 0.400 |
Why?
|
Breast Neoplasms | 2 | 2010 | 761 | 0.390 |
Why?
|
Angiotensins | 1 | 2011 | 42 | 0.380 |
Why?
|
Pre-Eclampsia | 4 | 2015 | 66 | 0.380 |
Why?
|
Lung Diseases, Interstitial | 1 | 2010 | 8 | 0.370 |
Why?
|
Astrocytes | 2 | 2013 | 58 | 0.370 |
Why?
|
Estradiol | 3 | 2011 | 128 | 0.370 |
Why?
|
Carcinoma, Ductal, Breast | 1 | 2010 | 30 | 0.360 |
Why?
|
Prostatic Neoplasms | 2 | 2012 | 470 | 0.360 |
Why?
|
Kidney | 8 | 2012 | 515 | 0.360 |
Why?
|
Mice | 13 | 2016 | 2475 | 0.350 |
Why?
|
Ovariectomy | 7 | 2010 | 149 | 0.350 |
Why?
|
Losartan | 8 | 2009 | 64 | 0.340 |
Why?
|
Cells, Cultured | 9 | 2013 | 833 | 0.330 |
Why?
|
Mitogen-Activated Protein Kinase Phosphatases | 1 | 2008 | 4 | 0.320 |
Why?
|
Muscle, Smooth, Vascular | 2 | 2008 | 63 | 0.320 |
Why?
|
Heart Ventricles | 2 | 2010 | 135 | 0.320 |
Why?
|
Mitogen-Activated Protein Kinases | 1 | 2008 | 37 | 0.320 |
Why?
|
Mitogen-Activated Protein Kinase 3 | 6 | 2015 | 43 | 0.320 |
Why?
|
Cyclooxygenase 2 | 2 | 2012 | 47 | 0.310 |
Why?
|
Myocytes, Smooth Muscle | 1 | 2008 | 72 | 0.310 |
Why?
|
Estrogen Receptor alpha | 1 | 2008 | 50 | 0.300 |
Why?
|
Angiotensinogen | 7 | 2012 | 59 | 0.300 |
Why?
|
Cell Division | 2 | 2005 | 95 | 0.300 |
Why?
|
Sodium Chloride, Dietary | 4 | 2012 | 28 | 0.300 |
Why?
|
Apolipoproteins E | 1 | 2008 | 94 | 0.300 |
Why?
|
Mice, Nude | 5 | 2012 | 290 | 0.300 |
Why?
|
Cell Line, Tumor | 6 | 2012 | 725 | 0.290 |
Why?
|
Male | 30 | 2020 | 19195 | 0.280 |
Why?
|
Xenograft Model Antitumor Assays | 4 | 2012 | 114 | 0.280 |
Why?
|
Rats, Inbred Lew | 12 | 2015 | 117 | 0.280 |
Why?
|
Tetrazoles | 8 | 2011 | 61 | 0.270 |
Why?
|
Linoleic Acids, Conjugated | 1 | 2005 | 7 | 0.260 |
Why?
|
Myocardium | 4 | 2020 | 186 | 0.260 |
Why?
|
Ventricular Remodeling | 4 | 2011 | 58 | 0.260 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2005 | 79 | 0.250 |
Why?
|
Aging | 6 | 2015 | 945 | 0.250 |
Why?
|
Humans | 21 | 2020 | 32024 | 0.250 |
Why?
|
Endocannabinoids | 2 | 2015 | 35 | 0.250 |
Why?
|
Medulla Oblongata | 3 | 2012 | 51 | 0.240 |
Why?
|
Female | 22 | 2020 | 19953 | 0.240 |
Why?
|
Evidence-Based Medicine | 2 | 2002 | 217 | 0.230 |
Why?
|
Neprilysin | 6 | 2012 | 31 | 0.230 |
Why?
|
Receptors, Angiotensin | 4 | 2013 | 61 | 0.220 |
Why?
|
Placenta | 4 | 2013 | 74 | 0.220 |
Why?
|
Pregnancy | 7 | 2015 | 994 | 0.220 |
Why?
|
Gene Expression Regulation, Enzymologic | 6 | 2015 | 80 | 0.220 |
Why?
|
Bone Marrow Cells | 3 | 2012 | 121 | 0.210 |
Why?
|
Mitogen-Activated Protein Kinase 1 | 4 | 2012 | 36 | 0.210 |
Why?
|
Chorionic Villi | 2 | 2015 | 7 | 0.210 |
Why?
|
Information Storage and Retrieval | 1 | 2002 | 22 | 0.200 |
Why?
|
Vascular Endothelial Growth Factor A | 3 | 2012 | 111 | 0.200 |
Why?
|
Hypertension, Renal | 3 | 2006 | 29 | 0.200 |
Why?
|
Malondialdehyde | 2 | 2020 | 11 | 0.200 |
Why?
|
Reactive Oxygen Species | 2 | 2020 | 157 | 0.190 |
Why?
|
Cardiomegaly | 2 | 2011 | 31 | 0.190 |
Why?
|
Muscle, Skeletal | 2 | 2016 | 518 | 0.190 |
Why?
|
Neovascularization, Pathologic | 2 | 2012 | 82 | 0.180 |
Why?
|
Catalase | 1 | 2020 | 15 | 0.180 |
Why?
|
Pancreas | 1 | 2001 | 104 | 0.180 |
Why?
|
New York City | 1 | 2020 | 14 | 0.180 |
Why?
|
Superoxide Dismutase | 1 | 2020 | 46 | 0.180 |
Why?
|
Brain | 4 | 2012 | 950 | 0.180 |
Why?
|
History, 21st Century | 1 | 2020 | 59 | 0.170 |
Why?
|
History, 20th Century | 1 | 2020 | 71 | 0.170 |
Why?
|
Mitral Valve | 1 | 2020 | 33 | 0.170 |
Why?
|
Phosphorylation | 4 | 2015 | 230 | 0.170 |
Why?
|
Animals, Newborn | 3 | 2012 | 115 | 0.170 |
Why?
|
Flavonoids | 2 | 2008 | 18 | 0.160 |
Why?
|
Fluorescent Antibody Technique | 2 | 2010 | 91 | 0.160 |
Why?
|
Protein Kinase Inhibitors | 2 | 2008 | 85 | 0.160 |
Why?
|
Disease Models, Animal | 9 | 2016 | 1017 | 0.150 |
Why?
|
Dipeptidyl-Peptidases and Tripeptidyl-Peptidases | 1 | 2017 | 6 | 0.150 |
Why?
|
Amino Acid Substitution | 1 | 2017 | 39 | 0.150 |
Why?
|
Up-Regulation | 4 | 2015 | 189 | 0.150 |
Why?
|
Lisinopril | 3 | 2006 | 26 | 0.150 |
Why?
|
Estrogens | 2 | 2010 | 167 | 0.150 |
Why?
|
Down-Regulation | 2 | 2015 | 142 | 0.150 |
Why?
|
Vasoconstrictor Agents | 4 | 2015 | 63 | 0.140 |
Why?
|
Proteinuria | 3 | 2011 | 59 | 0.140 |
Why?
|
Sarcoma, Experimental | 1 | 2016 | 4 | 0.130 |
Why?
|
Spasm | 1 | 2016 | 6 | 0.130 |
Why?
|
Autonomic Nervous System | 2 | 2012 | 43 | 0.130 |
Why?
|
Blotting, Western | 3 | 2010 | 292 | 0.130 |
Why?
|
Amidohydrolases | 1 | 2015 | 8 | 0.130 |
Why?
|
Monoacylglycerol Lipases | 1 | 2015 | 5 | 0.130 |
Why?
|
Receptors, Cannabinoid | 1 | 2015 | 25 | 0.120 |
Why?
|
Leptin | 3 | 2011 | 71 | 0.120 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 3 | 2015 | 261 | 0.120 |
Why?
|
Neoplasms | 2 | 2014 | 692 | 0.120 |
Why?
|
Intercellular Signaling Peptides and Proteins | 1 | 2015 | 104 | 0.120 |
Why?
|
Nitric Oxide Synthase Type I | 2 | 2012 | 17 | 0.120 |
Why?
|
Endothelin-1 | 3 | 2012 | 18 | 0.120 |
Why?
|
Transforming Growth Factor beta | 2 | 2015 | 64 | 0.120 |
Why?
|
Embryo Implantation | 1 | 2015 | 58 | 0.120 |
Why?
|
Rats, Transgenic | 5 | 2012 | 47 | 0.120 |
Why?
|
Animals, Genetically Modified | 7 | 2008 | 66 | 0.120 |
Why?
|
Stromal Cells | 2 | 2004 | 84 | 0.120 |
Why?
|
Radiation-Protective Agents | 1 | 2013 | 5 | 0.110 |
Why?
|
Pyridines | 4 | 2009 | 76 | 0.110 |
Why?
|
Amino Acid Sequence | 1 | 2014 | 283 | 0.110 |
Why?
|
Cyclopentanes | 2 | 2011 | 16 | 0.110 |
Why?
|
Quinolines | 2 | 2011 | 21 | 0.110 |
Why?
|
Heart | 2 | 2012 | 179 | 0.110 |
Why?
|
Benzopyrans | 1 | 2012 | 5 | 0.110 |
Why?
|
Sodium Chloride | 1 | 2012 | 22 | 0.110 |
Why?
|
Ethanolamines | 1 | 2012 | 9 | 0.110 |
Why?
|
Vascular Endothelial Growth Factor Receptor-1 | 1 | 2012 | 7 | 0.100 |
Why?
|
Ornithine | 1 | 2012 | 4 | 0.100 |
Why?
|
Mice, SCID | 1 | 2012 | 71 | 0.100 |
Why?
|
Signal Transduction | 3 | 2012 | 687 | 0.100 |
Why?
|
Clinical Trials as Topic | 1 | 2014 | 300 | 0.100 |
Why?
|
Mediodorsal Thalamic Nucleus | 1 | 2011 | 5 | 0.100 |
Why?
|
Phenylephrine | 2 | 2008 | 28 | 0.100 |
Why?
|
Neoplasm Metastasis | 1 | 2012 | 221 | 0.100 |
Why?
|
Bone Neoplasms | 1 | 2012 | 111 | 0.090 |
Why?
|
Immunoenzyme Techniques | 1 | 2010 | 52 | 0.090 |
Why?
|
Fibronectins | 1 | 2010 | 36 | 0.090 |
Why?
|
Tumor Cells, Cultured | 1 | 2010 | 168 | 0.090 |
Why?
|
Oligonucleotides, Antisense | 2 | 2012 | 30 | 0.090 |
Why?
|
Neuroglia | 2 | 2006 | 30 | 0.090 |
Why?
|
Angiogenesis Inhibitors | 1 | 2009 | 36 | 0.090 |
Why?
|
Valine | 2 | 2006 | 14 | 0.080 |
Why?
|
Immunoblotting | 2 | 2006 | 51 | 0.080 |
Why?
|
Mice, Knockout | 2 | 2008 | 444 | 0.080 |
Why?
|
Atrial Natriuretic Factor | 1 | 2008 | 10 | 0.080 |
Why?
|
Butadienes | 1 | 2008 | 8 | 0.080 |
Why?
|
Vanadates | 1 | 2008 | 2 | 0.080 |
Why?
|
Okadaic Acid | 1 | 2008 | 4 | 0.080 |
Why?
|
Kidney Diseases | 2 | 2012 | 249 | 0.080 |
Why?
|
Nitriles | 1 | 2008 | 23 | 0.080 |
Why?
|
Aorta, Thoracic | 2 | 2009 | 85 | 0.080 |
Why?
|
Ventricular Dysfunction, Left | 1 | 2009 | 170 | 0.080 |
Why?
|
Membranes | 1 | 2008 | 10 | 0.080 |
Why?
|
Radioimmunoassay | 1 | 2008 | 25 | 0.080 |
Why?
|
Pregnancy, Animal | 1 | 2007 | 19 | 0.080 |
Why?
|
Kinetics | 2 | 2006 | 209 | 0.080 |
Why?
|
Cell Growth Processes | 1 | 2007 | 8 | 0.070 |
Why?
|
Nitric Oxide Synthase | 1 | 2006 | 35 | 0.070 |
Why?
|
Reference Values | 3 | 2016 | 247 | 0.070 |
Why?
|
Models, Genetic | 1 | 2006 | 94 | 0.070 |
Why?
|
Lung | 1 | 2008 | 255 | 0.070 |
Why?
|
Electrophoresis, Polyacrylamide Gel | 1 | 2005 | 36 | 0.070 |
Why?
|
Lipid Peroxidation | 1 | 2005 | 33 | 0.070 |
Why?
|
Cerebellum | 1 | 2005 | 26 | 0.070 |
Why?
|
Forkhead Transcription Factors | 1 | 2005 | 27 | 0.060 |
Why?
|
Rats, Inbred SHR | 3 | 2012 | 31 | 0.060 |
Why?
|
Glycerides | 2 | 2015 | 13 | 0.060 |
Why?
|
Immunohistochemistry | 3 | 2016 | 532 | 0.060 |
Why?
|
Aged | 4 | 2012 | 10340 | 0.060 |
Why?
|
Arachidonic Acids | 2 | 2015 | 23 | 0.060 |
Why?
|
Arachidonic Acid | 1 | 2004 | 35 | 0.060 |
Why?
|
DNA-Binding Proteins | 1 | 2005 | 147 | 0.060 |
Why?
|
Gene Expression | 3 | 2013 | 335 | 0.060 |
Why?
|
Nitric Oxide | 3 | 2012 | 112 | 0.060 |
Why?
|
Time Factors | 4 | 2012 | 2152 | 0.060 |
Why?
|
Culture Media | 1 | 2004 | 47 | 0.060 |
Why?
|
Transcription Factors | 1 | 2005 | 180 | 0.060 |
Why?
|
DNA Replication | 1 | 2004 | 34 | 0.060 |
Why?
|
Cardiomyopathy, Hypertrophic | 1 | 2004 | 4 | 0.060 |
Why?
|
Carotid Arteries | 2 | 2005 | 99 | 0.060 |
Why?
|
Hematopoietic Stem Cells | 1 | 2004 | 100 | 0.060 |
Why?
|
Dinoprost | 1 | 2003 | 10 | 0.060 |
Why?
|
Microinjections | 2 | 2015 | 35 | 0.050 |
Why?
|
Random Allocation | 2 | 2016 | 220 | 0.050 |
Why?
|
National Library of Medicine (U.S.) | 1 | 2002 | 1 | 0.050 |
Why?
|
Subject Headings | 1 | 2002 | 1 | 0.050 |
Why?
|
Animals, Congenic | 3 | 2007 | 14 | 0.050 |
Why?
|
Analysis of Variance | 2 | 2016 | 464 | 0.050 |
Why?
|
Decidua | 2 | 2015 | 18 | 0.050 |
Why?
|
Research | 1 | 2002 | 74 | 0.050 |
Why?
|
Sensitivity and Specificity | 2 | 2016 | 594 | 0.050 |
Why?
|
Internet | 1 | 2002 | 195 | 0.050 |
Why?
|
Middle Aged | 2 | 2012 | 11868 | 0.050 |
Why?
|
Nitric Oxide Synthase Type III | 2 | 2012 | 36 | 0.040 |
Why?
|
Nitrates | 2 | 2012 | 27 | 0.040 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2002 | 507 | 0.040 |
Why?
|
Myocardial Infarction | 1 | 2004 | 485 | 0.040 |
Why?
|
Injections | 2 | 2012 | 64 | 0.040 |
Why?
|
Inflammation | 2 | 2013 | 540 | 0.040 |
Why?
|
Carotid Artery Diseases | 1 | 2000 | 114 | 0.040 |
Why?
|
Protein Stability | 1 | 2017 | 25 | 0.040 |
Why?
|
Benzimidazoles | 2 | 2006 | 28 | 0.030 |
Why?
|
Muscle Neoplasms | 1 | 2016 | 8 | 0.030 |
Why?
|
Mice, Inbred Strains | 1 | 2016 | 47 | 0.030 |
Why?
|
Pyrrolidonecarboxylic Acid | 1 | 2015 | 4 | 0.030 |
Why?
|
Hindlimb | 1 | 2016 | 54 | 0.030 |
Why?
|
Protein Precursors | 1 | 2015 | 22 | 0.030 |
Why?
|
Pregnancy Trimester, Third | 1 | 2015 | 18 | 0.030 |
Why?
|
Protein Isoforms | 1 | 2015 | 57 | 0.030 |
Why?
|
Tissue Culture Techniques | 1 | 2015 | 40 | 0.030 |
Why?
|
Biopsy, Needle | 1 | 2016 | 95 | 0.030 |
Why?
|
Body Weight | 2 | 2009 | 310 | 0.030 |
Why?
|
Gene Expression Regulation, Developmental | 1 | 2015 | 69 | 0.030 |
Why?
|
Receptor, Cannabinoid, CB2 | 1 | 2015 | 17 | 0.030 |
Why?
|
Protein Processing, Post-Translational | 1 | 2015 | 78 | 0.030 |
Why?
|
Pseudopregnancy | 1 | 2015 | 4 | 0.030 |
Why?
|
Infusion Pumps | 1 | 2015 | 5 | 0.030 |
Why?
|
Smad2 Protein | 1 | 2015 | 6 | 0.030 |
Why?
|
Arterioles | 1 | 2015 | 13 | 0.030 |
Why?
|
Connective Tissue Growth Factor | 1 | 2015 | 7 | 0.030 |
Why?
|
Smad3 Protein | 1 | 2015 | 10 | 0.030 |
Why?
|
Pyrazoles | 1 | 2015 | 67 | 0.030 |
Why?
|
Mass Spectrometry | 1 | 2015 | 103 | 0.030 |
Why?
|
Receptor, Cannabinoid, CB1 | 1 | 2015 | 56 | 0.030 |
Why?
|
Piperidines | 1 | 2015 | 117 | 0.030 |
Why?
|
Adult | 3 | 2015 | 9366 | 0.030 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2013 | 62 | 0.030 |
Why?
|
Myometrium | 1 | 2013 | 11 | 0.030 |
Why?
|
United States | 1 | 2002 | 3938 | 0.030 |
Why?
|
Chronic Disease | 1 | 2015 | 401 | 0.030 |
Why?
|
Gestational Age | 1 | 2013 | 120 | 0.030 |
Why?
|
JNK Mitogen-Activated Protein Kinases | 1 | 2012 | 14 | 0.030 |
Why?
|
Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 1 | 2012 | 18 | 0.030 |
Why?
|
Ion Channels | 1 | 2012 | 24 | 0.030 |
Why?
|
Biopterin | 1 | 2012 | 3 | 0.030 |
Why?
|
Pregnancy Proteins | 1 | 2012 | 13 | 0.030 |
Why?
|
Nitrites | 1 | 2012 | 21 | 0.030 |
Why?
|
Gene Transfer Techniques | 1 | 2012 | 63 | 0.030 |
Why?
|
Prostaglandin-Endoperoxide Synthases | 1 | 2012 | 31 | 0.030 |
Why?
|
Mitochondrial Proteins | 1 | 2012 | 66 | 0.030 |
Why?
|
Drug Interactions | 1 | 2011 | 79 | 0.020 |
Why?
|
Mesenteric Arteries | 1 | 2011 | 20 | 0.020 |
Why?
|
Age Factors | 1 | 2015 | 1194 | 0.020 |
Why?
|
Dual-Specificity Phosphatases | 1 | 2011 | 5 | 0.020 |
Why?
|
Sodium, Dietary | 1 | 2011 | 23 | 0.020 |
Why?
|
Kidney Tubules, Proximal | 1 | 2011 | 40 | 0.020 |
Why?
|
Gene Expression Profiling | 1 | 2012 | 323 | 0.020 |
Why?
|
Rats, Inbred F344 | 1 | 2011 | 133 | 0.020 |
Why?
|
Vasodilation | 1 | 2011 | 93 | 0.020 |
Why?
|
Models, Animal | 1 | 2011 | 164 | 0.020 |
Why?
|
Mitochondria | 1 | 2012 | 186 | 0.020 |
Why?
|
Collagen | 1 | 2012 | 225 | 0.020 |
Why?
|
Regression Analysis | 1 | 2011 | 294 | 0.020 |
Why?
|
DNA | 1 | 2012 | 228 | 0.020 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 155 | 0.020 |
Why?
|
Bradycardia | 1 | 2009 | 16 | 0.020 |
Why?
|
Chorioallantoic Membrane | 1 | 2009 | 4 | 0.020 |
Why?
|
Sympathetic Nervous System | 1 | 2009 | 31 | 0.020 |
Why?
|
Stereoisomerism | 1 | 2009 | 22 | 0.020 |
Why?
|
Injections, Subcutaneous | 1 | 2009 | 35 | 0.020 |
Why?
|
Alanine | 1 | 2009 | 27 | 0.020 |
Why?
|
Probability | 1 | 2009 | 158 | 0.020 |
Why?
|
Chick Embryo | 1 | 2009 | 74 | 0.020 |
Why?
|
Peptides | 1 | 2009 | 119 | 0.020 |
Why?
|
Polymerase Chain Reaction | 1 | 2009 | 197 | 0.020 |
Why?
|
Neovascularization, Physiologic | 1 | 2009 | 110 | 0.020 |
Why?
|
Organ Size | 1 | 2009 | 210 | 0.020 |
Why?
|
Biguanides | 1 | 2008 | 3 | 0.020 |
Why?
|
Young Adult | 1 | 2015 | 2615 | 0.020 |
Why?
|
Sex Factors | 1 | 2010 | 663 | 0.020 |
Why?
|
Yolk Sac | 1 | 2007 | 2 | 0.020 |
Why?
|
Endothelial Cells | 1 | 2009 | 189 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2009 | 629 | 0.020 |
Why?
|
Hypertension, Pregnancy-Induced | 1 | 2007 | 13 | 0.020 |
Why?
|
Hypertrophy | 1 | 2007 | 26 | 0.020 |
Why?
|
Cell Adhesion Molecules | 1 | 2007 | 45 | 0.020 |
Why?
|
Models, Biological | 1 | 2009 | 391 | 0.020 |
Why?
|
Amnion | 1 | 2007 | 37 | 0.020 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2007 | 73 | 0.020 |
Why?
|
Insulin-Like Growth Factor I | 1 | 2007 | 83 | 0.020 |
Why?
|
Nitric Oxide Synthase Type II | 1 | 2006 | 14 | 0.020 |
Why?
|
Epithelial Cells | 1 | 2007 | 142 | 0.020 |
Why?
|
Aminopeptidases | 1 | 2006 | 3 | 0.020 |
Why?
|
Aldosterone | 1 | 2006 | 26 | 0.020 |
Why?
|
Kidney Cortex | 1 | 2006 | 25 | 0.020 |
Why?
|
Kidney Medulla | 1 | 2006 | 29 | 0.020 |
Why?
|
Isoenzymes | 1 | 2006 | 61 | 0.020 |
Why?
|
Crosses, Genetic | 1 | 2006 | 20 | 0.020 |
Why?
|
Microscopy, Electron, Transmission | 1 | 2006 | 32 | 0.020 |
Why?
|
Heterozygote | 1 | 2006 | 57 | 0.020 |
Why?
|
Podocytes | 1 | 2006 | 20 | 0.020 |
Why?
|
C-Reactive Protein | 1 | 2007 | 239 | 0.020 |
Why?
|
Kidney Glomerulus | 1 | 2006 | 30 | 0.020 |
Why?
|
Enzyme Inhibitors | 1 | 2006 | 165 | 0.020 |
Why?
|
Tail | 1 | 2005 | 5 | 0.020 |
Why?
|
Membrane Proteins | 1 | 2007 | 257 | 0.020 |
Why?
|
Atenolol | 1 | 2005 | 6 | 0.020 |
Why?
|
Hydralazine | 1 | 2005 | 7 | 0.020 |
Why?
|
Sex Characteristics | 1 | 2006 | 171 | 0.020 |
Why?
|
Albuminuria | 1 | 2006 | 181 | 0.020 |
Why?
|
Cohort Studies | 1 | 2009 | 1831 | 0.020 |
Why?
|
Adrenergic beta-Antagonists | 1 | 2005 | 61 | 0.020 |
Why?
|
Macrophage Colony-Stimulating Factor | 1 | 2004 | 5 | 0.020 |
Why?
|
Vasodilator Agents | 1 | 2005 | 61 | 0.020 |
Why?
|
Cell Lineage | 1 | 2004 | 71 | 0.010 |
Why?
|
Polyuria | 1 | 2004 | 3 | 0.010 |
Why?
|
Diuresis | 1 | 2004 | 6 | 0.010 |
Why?
|
Enzyme Induction | 1 | 2004 | 32 | 0.010 |
Why?
|
Ligation | 1 | 2004 | 56 | 0.010 |
Why?
|
Organ Specificity | 1 | 2004 | 80 | 0.010 |
Why?
|
Hypotension | 1 | 2004 | 47 | 0.010 |
Why?
|
F2-Isoprostanes | 1 | 2003 | 20 | 0.010 |
Why?
|
Macaca fascicularis | 1 | 2004 | 397 | 0.010 |
Why?
|
Insulin | 1 | 2005 | 366 | 0.010 |
Why?
|
Coronary Vessels | 1 | 2004 | 160 | 0.010 |
Why?
|
Chemoreceptor Cells | 1 | 2002 | 2 | 0.010 |
Why?
|
Substance P | 1 | 2002 | 20 | 0.010 |
Why?
|
Vagus Nerve | 1 | 2002 | 29 | 0.010 |
Why?
|
Aged, 80 and over | 1 | 2009 | 4000 | 0.010 |
Why?
|
Hemodynamics | 1 | 2002 | 155 | 0.010 |
Why?
|
Disease Progression | 1 | 2003 | 594 | 0.010 |
Why?
|
In Situ Hybridization | 1 | 2000 | 38 | 0.010 |
Why?
|
Endarterectomy, Carotid | 1 | 2000 | 30 | 0.010 |
Why?
|
Macrophages | 1 | 2000 | 192 | 0.010 |
Why?
|